John Libbey Eurotext

Médecine de la Reproduction


What reproductive follow-up for women after cancer? Volume 24, issue 1, Janvier-Février-Mars 2022


  • Figure 1.
  • Figure 2.
Service d’AMP et préservation de la fertilité, hôpital Jeanne de Flandre, CHU Lille, France

There are two main arguments in favour of systematic reproductive monitoring in young women treated for cancer: 1) to assess follicular loss induced by chemotherapy or pelvic radiotherapy, as well as spontaneous fertility, in order to refine fertility preservation (FP) strategies prior to treatment, 2) to judge the interest of a second FP phase at a distance from the disease according to the degree of ovarian recovery. Longitudinal monitoring of anti-müllerian hormone, a realtime reflection of follicular loss and recovery during treatment, makes it possible to classify chemotherapy protocols according to their degree of ovarian toxicity, thus making it possible to develop decision trees for FP before and after the disease.